title: EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
abstract: Current development of targeted therapy in oncology is particularly active and concerns principally two types of agents which are monoclonal antibodies (Mabs) and tyrosine kinase inhibitors (TKIs). Epidermal growth factor receptor (EGFR) signaling pathways play a key role in the regulation of cell proliferation, survival and differentiation. Consequently, EGFR is one of the most-studied ligand-receptor systems and specific EGFR inhibition approaches are currently among the most promising and the most advanced in the clinical setting. Cetuximab (Erbitux), belonging to the Mabs family, gefitinib (Iressa) and erlotinib (Tarceva), belonging to the TKIs family, are among the most advanced anti-EGFR drugs at the clinical level. The aim of this review article is to compare at both experimental and clinical levels the key points which govern the activity of these two types of targeting agents.
authors.affiliation: Centre Antoine Lacassagne, Laboratoire d'Oncopharmacologie, 33 Avenue de Vallombrose, 06189 Nice, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Dassonville
authors.forename: Alexandre
authors.initials: A
authors.lastname: Bozec
authors.forename: Jean Louis
authors.initials: JL
authors.lastname: Fischel
authors.forename: Gerard
authors.initials: G
authors.lastname: Milano
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000378:metabolism / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases